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سرطان خلية بالزما الدم األولية
تقرير حالة ومراجعة األدبيات
�شاريكا �شينج، أشوتش راث، �شوريكا ياداف
abstract: Plasma cell leukaemia (PCL) is one of the most aggressive and rarest forms of plasma cell dyscrasia. How- 
ever, the diagnostic criteria for this condition have not yet been revised and there is no specific treatment to signif-
icantly improve the course of the disease. We report a 69-year-old male who presented to the Lok Nayak Hospital, 
New Delhi, India, in 2017 with dyspnoea and chest pain. A peripheral blood smear showed an absolute plasma cell 
count of 2.16 × 109/L. A bone marrow examination showed 61% atypical plasma cells exhibiting kappa light chain 
restriction. Biochemical investigations were consistent with a diagnosis of primary PCL with renal involvement. 
Bortezomib-based chemotherapy was initiated, which resulted in an improvement in the patient’s haematological 
and biochemical parameters. This case report includes a comprehensive review of the clinical and diagnostic features, 
pathobiology and treatment of PCL.
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امللخ�ص: �رسطان خلية بالزما الدم الأولية هي واحدة من الأ�شكال الأكرث عدوانية واأندر اأعتاللت خلية البالزما. ومع ذلك ، مل يتم بعد 
تنقيح املعايري الت�شخي�شية لهذه احلالة ول يوجد عالج حمدد لتح�شني م�شار املر�ص ب�شكل كبري. هذا تقرير عن حالة ذكر يبلغ من العمر 
69 عاًما قدم اإىل م�شت�شفى لوك ناياك يف نيودلهي بالهند عام 2017 ب�شبب �شيق يف التنف�ص واأمل يف ال�شدر. واأظهر الفح�ص املجهري 
للدم وجود عدد من خاليا البالزما يبلغ L/109 × 2.16 لرت. كما اأظهر فح�ص لنخاع العظم اأن %61 من خاليا البالزما غري النمطية التي 
تظهر قيوًدا على �شل�شلة الكابا اخلفيفة لالأج�شام امل�شادة. كانت التحريات البيوكيميائية مت�شقة مع ت�شخي�ص �رسطان خلية بالزما الدم 
الأولية مع تاأثر الكلى باملر�ص. وبداأ العالج الكيميائي بوا�شطة عقار البورتيزوميب ، مما اأدى اإىل حت�شن يف موؤ�رسات �شورة الدم ونتائج 
الفحو�شات الكيميائية للمري�ص. يت�شمن تقرير احلالة هذا مراجعة �شاملة للخ�شائ�ص ال�رسيرية والت�شخي�شية ، واملر�شية وطرق عالج 
�رسطان خلية بالزما الدم الأولية.
الكلمات املفتاحية: �رسطان خلية بالزما الدم؛ املايلوما املتعددة؛ خاليا البالزما؛ تقرير حالة؛ الهند.
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A 69-year-old male presented to a local hospital in New 
Delhi, India, in 2017 with a two-month history of rectal 
bleeding and dyspnoea during routine activities. Heart 
disease was suspected and the patient was managed 
accordingly, with minimal investigations. Despite transient 
improvement, he subsequently presented to the Lok Nayak 
Hospital, New Delhi, in 2017 with dyspnoea and chest 
pain. During a general physical examination, there was 
evidence of pallor without lymphadenopathy. A systemic 
examination was unremarkable with no evidence of hepa- 
tosplenomegaly.
A complete blood count revealed anaemia with a 
haemoglobin (Hb) level of 72 g/L, mild leukocytosis with 
a total leukocyte count (TLC) of 12 × 109/L and thrombo- 
cytopaenia with a platelet count of 97 × 109/L. The eryth- 
rocyte sedimentation rate was 70 mm/hour. A peripheral 
Plasma cell leukaemia (pcl) is a rare and aggressive form of plasma cell dyscrasia.1 Primary PCL occurs de novo, whereas secondary PCL is 
the leukaemic transformation of relapsed or refractory 
multiple myeloma (MM). The incidence of PCL is 2–4%, 
of which 60–70% of cases are primary and 30–40% are 
secondary, although the incidence of the latter type is 
rising.2,3 The median age of patients with primary PCL 
is younger than those with secondary PCL (52–65 years 
old versus 65–70 years old).2 In a case series by Rajeswari 
et al., four out of 16 patients with PCL were under the 
age of 40 years, with the youngest being 25 years old.4 
Although primary and secondary PCL are considered 
different clinical entities, both have a poor prognosis. 
The median survival rate ranges from 6.8–12.6 months 
without novel therapy, although this increases to 
over three years after autologous stem cell transplant- 
ation.1,5 
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blood smear exhibited normocytic/normochromic to 
microcytic/hypochromic red blood cells with extensive 
rouleaux formation. A differential leukocyte count rev-
ealed 18% plasma cells with an absolute platelet cell count 
of 2.16 × 109/L and 15% atypical lymphocytes [Figure 1]. 
Mature plasma cells as well as plasma cells with bipolar 
cytoplasm were present. The atypical lymphocytes had 
central and eccentrically placed nuclei and a moderate 
amount of cytoplasm with fuzzy cytoplasmic borders.
A bone marrow examination was performed to 
establish the extent of PCL involvement. A bone marrow 
aspirate smear and haematoxylin and eosin stain showed 
61% atypical plasma cells [Figure 2]. The morphological 
spectrum of these cells included thesaurocytes, plasma 
cells with bipolar cytoplasm and one to two prominent 
nucleoli in the nucleus and binucleated plasma cells. The 
bone marrow was hypercellular for age and showed the 
near-total replacement of the marrow spaces by the 
plasma cells, with focal areas of haematopoietic cells. 
Upon immunohistochemical analysis, the plasma cells 
were immunoreactive for cluster of differentiation 
(CD)38, showed kappa light chain restriction and reduced 
lambda light chain expression and demonstrated focal 
positivity for CD20 [Figure 3]. The cells were immuno-
negative for CD19 and p53.
Biochemical investigations showed high levels of 
serum creatinine (3.3 mg/dL; normal range: 0.6–1.2 mg/dL), 
blood urea (147 mg/dL; normal range: 8–23 mg/dL) and 
serum uric acid (13.0 mg/dL; normal range: 4–8.5 mg/dL). 
However, serum calcium levels were slightly low 
(8.5 mg/dL; normal range: 9.2–11 mg/dL). Radiolog- 
ical investigations, including a chest X-ray, abdominal 
ultrasound and skeletal survey, did not show any lesions. 
Serum protein electrophoresis indicated a total protein 
level of 15.20 g/dL (normal range: 6.40–8.10 g/dL), albu- 
min level of 3.83 g/dL (normal range: 3.50–5.64 g/dL), α1-
globulin level of 0.62 g/dL (normal range: 0.17–0.41 g/dL), 
α2-globulin level of 1.19 g/dL (normal range: 0.31–0.85 
g/dL), β-globulin level of 0.59 g/dL (normal range: 
0.49–1.32 g/dL), γ-globulin level of 8.97 g/dL (normal 
range: 0.62–1.53 g/dL) and albumin/globulin ratio of 
0.34 (normal ratio: 0.90–2.00). Furthermore, the γ-glob- 
ulin region showed a monoclonal spike. The raised glob- 
ulins were found to be immunoglobulin (Ig)D on serum 
immunofixation electrophoresis. Bence Jones proteins 
were absent in the urine. A serum free light chain assay 
revealed kappa light chain restriction with elevated 
kappa free light chains at 204.00 mg/L (normal range: 
3.30–19.40 mg/L) and a kappa/lambda ratio of 27.72 
(normal ratio: 0.26–1.65). Serum β2-microglobulins 
were markedly raised at 15,576 ng/mL (normal range: 
609–2,366 ng/mL).
Following confirmation of the diagnosis of primary 
PCL, the patient decided to undergo treatment at an onc-
ology centre, at which point bortezomib-based chemo- 
therapy was initiated. However, a follow-up haematol-
ogical profile was performed at the Lok Nayak Hospital. 
After the first cycle of chemotherapy, the patient’s TLC 
was 8.72 × 109/L, Hb level was 106 g/L, platelet count was 
157 × 109/L, serum creatinine level was 1.4 mg/dL and 
blood urea level was 27 mg/dL. On day 11 of the first 
cycle, a peripheral blood smear did not show any plasma 
cells. At the time of writing, the patient was stable; 
however, a follow-up bone marrow examination had 
not yet been performed to assess his remission status.
 
Figure 1: Peripheral blood smears at x200 magnification 
showing (A) rouleaux formation, plasma cells (arrows) and 
(B) atypical lymphocytes (arrowhead).
 
Figure 3: Immunohistochemistry panel at x400 magnif- 
ication showing (A) positivity for cluster of differentiation 
(CD)38, (B) kappa light chain restriction, (C) reduced 
lambda light chain expression and (D) focal positivity 
for CD20.
 
Figure 2: A: Bone marrow aspirate smear at x1,000 magnif- 
ication showing atypical plasma cells (arrows). B: Haemat- 
oxylin and eosin stain at x400 magnification showing plasma 
cells.
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Patients may also present with other clinical features, 
such as organomegaly, lymphadenopathy, pleural effusion 
and central nervous system involvement leading to neuro- 
logical deficits and extramedullary plasmacytomas. In 
the current case, the patient initially presented with 
bleeding from the rectum and dyspnoea. Renal involve-
ment can also occur, presenting as acute kidney failure, 
with studies indicating this is more commonly associated 
with PCL than MM (53–62% versus 22–43%).11,12 A 
renal biopsy may show interstitial plasma cell infiltration, 
tubular casts and light chain restriction with direct 
immunofluorescence.13 The current case also showed 
renal involvement with raised blood urea and serum 
creatinine levels which normalised after chemotherapy.
Certain parameters can help to differentiate PCL 
from MM, including leukocytosis, relatively high levels 
of serum lactate dehydrogenase and β2-microglobulins 
and lower frequencies of lytic bone lesions.1 In addition, 
patients with PCL usually only secrete free light chains, 
unlike those with MM. Moreover, plasma cells in PCL 
cases often show varying morphologies, ranging from 
classic plasma cells, plasmablasts and hairy-cell-like 
morphology to marked anaplastic features.4,14 In the 
current case, 15% of the lymphocytes were atypical in that 
their morphology differed from that of either classic or 
atypical plasma cells; instead, the cells resembled mature 
lymphocytes with fuzzy cytoplasmic borders. Previous 
case reports have documented similar lymphocyte-like 
morphologies in PCL cases.15–17 Although flow cyto-
metry can help establish the actual nature of such cells, 
this could not be performed in the current case as the 
patient had been referred to an external oncology centre. 
The diagnostic criteria for PCL were initially laid 
down by Noel et al. in 1974 and include the presence of 
>20% of plasma cells ascertained to be clonal in nature 
in the peripheral blood or an absolute plasma cell count 
of >2 × 109/L.18,19 However, the presence of plasma cells 
Discussion
Myeloma cells are dependent for their survival on inter-
actions with the bone marrow microenvironment.6 
Myeloma cells require CD56—a neuronal cell adhesion 
molecule—to anchor to the bone marrow stroma. As 
CD56 expression decreases, myeloma cells gain access 
to the peripheral blood due to loss of contact with the 
bone marrow stroma. Patients with PCL therefore 
usually show decreased expression of CD56.7 Other 
molecules, such as CD27, CD117 and human leuk-
ocyte antigen-DR isotype, are usually negative, whereas 
CD19, CD20 and CD23 are often positive. In addition, 
cases of secondary PCL often show CD28 positivity.5 
Interleukin-6 is considered an important cytokine for 
PCL proliferation.8 
In most primary PCL cases, genetic aberrancies 
are already present at the time of diagnosis; in contrast, 
the gradual accumulation of various genetic mutations 
make MM more aggressive, resulting in secondary PCL.1 
Hypodiploidy or diploidy are present in 80% of PCL 
cases and are considered poor prognostic factors comp- 
ared to hyperdiploidy, a common feature of MM.9 Both 
forms of PCL commonly show IgH translocations, 
notably in chromosome 14q32. Furthermore, amplif-
ications of chromosome 1q21, MYC abnormalities and 
Ras mutations are more frequently seen in PCL than 
MM.10 In addition, 11q13 (cyclin D1) translocations 
are almost exclusive to primary PCL.1 However, Tp53 
inactivation has been observed in both forms of PCL.2 
It has been suggested that a phosphatase and tensin 
homolog deletion is responsible for the transition of 
MM to PCL.5
Due to extensive infiltration of the bone marrow 
by atypical plasma cells, the most common symptoms 
of PCL are related to severe anaemia and thrombocyt-
opaenia, notably dyspnoea and haemorrhagic diathesis.1 
Table 1: Remission criteria per category for plasma cell leukaemia cases5
Category Plasma cells M-protein levels Extramedullary 
disease
Peripheral blood Bone marrow Serum Urinary
Complete remission Absent <5% Negative Negative Absent
Stringent complete 
remission
Absent Undetectable by 
flow cytometry
Negative Negative Absent
Very good partial response Absent <5% ≥90% 
reduction
<100 mg/24 hours Absent
Partial response 1–5% 5–25% ≥50% 
reduction
<200 mg/24 hours ≥50% reduction
Progressive disease >5% absolute 
increase
>25% increase or 
absolute increase 
of ≥10%
>25% increase >25% increase Definite increase
Stable disease None of the above criteria are met
Relapse Reappearance >10% increase Reappearance Reappearance Any disease
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in peripheral blood can also be seen in other plasma 
cell dyscrasias and certain non-malignant conditions 
such as severe sepsis and infectious mononucleosis.20 
It has therefore been suggested that the diagnostic 
criteria of PCL should be revised to >5% plasma cells or 
an absolute plasma count of >0.5 × 109/L so as to avoid 
underdiagnosis of the condition.5 However, although 
the flow cytometric evaluation of PCL and revision of 
the criteria for diagnosis is currently under consider-
ation, there is no consensus yet as further prospective 
multicentre analyses are required.
In terms of treatment, the proteasome inhibitor 
bortezomib has shown a relatively good response in both 
primary and secondary PCL, resulting in some cases in 
complete remission.21 Bortezomib combined with dexa- 
methasone and melphalan has also been documented 
to show a good response, whereas thalidomide and lena- 
lidomide have only shown a transient partial response.5 
Allogenic stem cell transplantation can be considered in 
patients under 50 years of age; however, the risk of trans- 
plantation-related mortality is increased.1,5 Nevertheless, 
high-dose chemotherapy followed by autologous stem 
cell transplantation improves survival, although mainly 
for patients with primary PCL.2
Seven categories of PCL remission have been 
proposed by the International Myeloma Working Group, 
based on the following four main parameters: (1) the 
plasma cell count in the peripheral blood; (2) the plasma 
cell count in the bone marrow; (3) serum and urinary 
M-protein levels; and (4) the assessment of extramed-
ullary disease [Table 1].5 In general, a patient is considered 
to be in complete remission if plasma cells are absent 
from the peripheral blood and there are <5% of plasma 
cells in the bone marrow. However, relapse is denoted 
by a >10% increase in bone marrow plasma cells with 
the reappearance of peripheral blood plasma cells and 
M-protein, along with evidence of extramedullary 
disease.5 Jelinek et al. also recommended the assessment 
of minimal residual disease-negative remission by multi-
colour flow cytometry or allele-specific oligonucleotide 
polymerase chain reaction.1
Conclusion
Various significant yet subtle parameters can be used 
to differentiate primary PCL from MM. As the survival 
rate is low, such information is necessary to ensure that 
PCL cases can be diagnosed early and appropriate treat- 
ment regimens initiated.
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